Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  15.00 1.69% 905.00 27,626 08:00:00
Bid Price Offer Price High Price Low Price Open Price
880.00 930.00 905.00 905.00 905.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -10.61 -16.00 538
Last Trade Time Trade Type Trade Size Trade Price Currency
08:27:39 O 467 880.00 GBX

Renalytix Ai (RENX) Latest News

More Renalytix Ai News
Renalytix Ai Investors    Renalytix Ai Takeover Rumours

Renalytix Ai (RENX) Discussions and Chat

Renalytix Ai (RENX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
08:27:40880.004674,109.60O
08:15:37905.0025,000226,250.00O
08:12:44927.50983.48O
08:02:43928.211,40012,994.92O
08:02:28905.5099896.45O
View all Renalytix Ai trades in real-time

Renalytix Ai (RENX) Top Chat Posts

DateSubject
08/3/2021
08:20
Renalytix Ai Daily Update: Renalytix Ai Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENX. The last closing price for Renalytix Ai was 890p.
Renalytix Ai Plc has a 4 week average price of 850p and a 12 week average price of 460p.
The 1 year high share price is 975p while the 1 year low share price is currently 173.50p.
There are currently 59,416,134 shares in issue and the average daily traded volume is 130,721 shares. The market capitalisation of Renalytix Ai Plc is £537,716,012.70.
24/2/2021
15:38
sspurt: Not sure today's announcement amounts to much at all. Reading through it no revenue $$$s are mentioned and RENX will actually be providing financial support i.e costs over a five year period. This is an existing relationship with RENX establishing a lab at the University last year so it doesn't seem to have moved the dial on at all as far as I can see. More interesting is the timing of the announcement, why not wait until the figs next week?
11/2/2021
15:36
wan: Agree that what I (managed to) hear thus far, is mind blowing in terms of being at the beginning of a treatment revolution! Jennifer Erickson eloquently described this as being a remarkable moment in time in terms of progress, regulatory change, and the innovation to address kidney disease/care. I am very pleased indeed to be invested across the space via both Renalytix and Verici (thank you EKF!), and not just because of the share price performance of both, which in my view are at the early stage of 'starting' to reflect the (unfortunately) enormous opportunities, but we have investments that look set to make a difference to health care and importantly patients....a big difference! I note that investors are liking the Presentation too!
10/2/2021
17:56
wan: Late news - FDA Adds Kantaro's Semi-Quantitative COVID-19 Antibody Test to Revised Emergency Use Authorization for Convalescent Plasma 10/02/2021 4:31pm PR Newswire (US) NEW YORK, Feb. 10, 2021 /PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Corporation (NASDAQ: TECH), announced that the U.S. Food and Drug Administration (FDA) has added COVID-SeroKlir to the Emergency Use Authorization (EUA) for the use of convalescent plasma for treating COVID-19 in hospitalized patients. COVID-SeroKlir detects the presence and precise level of SARS-CoV-2 IgG antibodies with 98.8% sensitivity and 99.6% specificity. he revised EUA qualifies the COVID-SeroKlir test for detecting high titer COVID-19 convalescent plasma during manufacturing. The EUA limits the use of high titer COVID-19 convalescent plasma only to treat hospitalized patients early in the disease course. COVID-19 convalescent plasma is an investigational product and is not currently approved or licensed for any indication. "We are pleased the FDA has added Kantaro's COVID-SeroKlir antibody test to the EUA for convalescent plasma and authorized the test's use in qualifying convalescent plasma titers," said Erik Lium, PhD, Chairman of the Board of Kantaro and Executive Vice President and Chief Commercial Innovation Officer at the Mount Sinai Health System. "We believe semi-quantitative antibody testing can play an important role in the development of advanced therapeutics for COVID-19 and appreciate that it is being recognized as such." The high performance of COVID-SeroKlir results from a two-step process that detects antibodies against two virus antigens, the full-length spike protein and its receptor-binding domain. This precision makes the Kantaro test accurate, with a low potential for false results. Mount Sinai developed the test's underlying technology, which has been used close to 90,000 times on a highly diverse patient population. COVID-SeroKlir received Emergency Use Authorization by the FDA in November 2020. hTTp://uk.advfn.com/stock-market/london/RENX/share-news/FDA-Adds-Kantaros-Semi-Quantitative-COVID-19-Antib/84298742?xref=newsalert
05/2/2021
14:24
hpcg: I have been pondering that once revenue starts to become apparent this could be a candidate for Cathie Wood's ARK ETF. It ticks her thematic box certainly. Actually making a profit early on might be as issue and would certainly be a mark against but nothing the company can do about that ;-). She has so much money to deploy that I'm sure they are looking far and wide for opportunities. Share price would be unlimited if she did take a liking.
16/1/2021
08:32
donald pond: I just can't make sense of those margins. I had in mind the basic cost was $925 a test, and while we may share a big chunk of that with third parties, surely the margin is still going to be very high?There's a chap on twitter, Dirk Gently, who was also explaining VRCI to me, he knows his stuff and that looks great.I do love the free spin off shares these companies generate. We got one VRCI share we got for each RENX one, so for anyone holding from that time you can add another 70p to the RENX share price to work out where you are.
01/1/2021
09:12
74tom: Indeed, closed at $16 which is £5.93 equivalent. It was also significant as RNLX broke out of a 3 month ascending triangle on no news and 2 x average volume, which is bullish whichever way you cut it. US Buyers wanted shares and were happy to pay up for them. My belief is that the pending FDA approval will be a true inflection point, it will derisk things considerably & likely lead to the next batch of healthcare systems adopting KidneyIntelX (remember James McCulloch was still bullish on integrating with 3 new systems before the end of June 21 on 27th October results call). It’s been a quiet news period of late, but hopefully the new year can herald the next phase of progress, both operationally & from a share price point of view.
31/12/2020
05:45
wan: There are many reasons for Renalytix Valuation, such as the track record, experience, and connections of the management team, which includes a deep relationship with Mount Sinai (a significant shareholder and launch partner) which encompasses the Icahn School of Medicine at Mount Sinai and eight hospital campuses in the New York metropolitan area. Importantly, each year kidney disease kills more people than breast and prostate cancer. Not to mention that the FDA has granted Breakthrough Device designation to KidneyIntelX™ 'effectively' demonstrating that both of the following criteria are met: 1. The device provides for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions 2, The device also meets at least one of the following: 1. Represents Breakthrough Technology 2. No Approved or Cleared Alternatives Exist 3. Offers Significant Advantages over Existing Approved or Cleared Alternative 4. Device Availability is in the Best Interest of Patients FDA grants Breakthrough Device designation to KidneyIntelX™ MAY 2, 2019 Provides priority regulatory review of AI-enabled diagnostic for fast-progressing kidney disease Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces that it has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA), for its lead diagnostic, KidneyIntelX™. This is the first such designation for an AI-enabled diagnostic for kidney disease publicly announced by any company. KidneyIntelXTM is designed to diagnose and improve clinical management of patients with Type II diabetes with fast-progressing kidney disease, in an effort to curtail the estimated $114 billion annual cost1 of chronic and end-stage kidney disease to the United States healthcare system. The diagnostic will use machine learning algorithms to assess the combination of predictive blood-based biomarkers, including sTNFR1, sTNFR2 and KIM1, in combination with electronic health record information, to identify progressive kidney disease. KidneyIntelXTM is being developed in close collaboration with the Mount Sinai Health System. The FDA’s Breakthrough Devices Program is a voluntary programme for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the programme is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment and review, while preserving the statutory standards for premarket approval, 510(k) clearance and De Novo marketing authorisation, consistent with the Agency’s mission to protect and promote public health. Sally Bowden, Chief Operating Officer of RenalytixAI, said: “This designation is a significant advancement towards our goal of bringing to market a solution that can greatly improve the identification and treatment of patients with chronic kidney disease. We look forward to continuing to work closely with the FDA through this process, including on our data development plan, our clinical validation and our subsequent submission for regulatory clearance.” Erik Lium, PhD, Executive Vice President of Mount Sinai Innovation Partners, said: “We’re pleased RenalytixAI has received Breakthrough Designation for KidneyIntelX, providing the opportunity to work hand-in-hand with the FDA towards the goal of FDA submission. Renal disease represents an increasing healthcare crisis globally, and early detection and intervention is essential in changing the course of this disease.” A copy of the FDA’s guidelines on the Breakthrough Devices Program can be found at GuidanceDocuments. Notes: [1] United States Renal Data System – hxxps://www.usrds.org/adrhighlights.aspx. The person responsible for arranging the release of this announcement on behalf of the Company is James McCullough, CEO. hTTps://renalytixai.com/fda-kidneyintelx-02-05-19/ The collaboration with a pharmaceutical and biopharmaceutical giant, AstraZeneca, to improve outcomes for patients with chronic disease (not just CKD) is another example, with the results from the program anticipated in early 2021 - NEW YORK, August 21, 2020 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), today announced a collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases. The first stage in the collaboration will use KidneyIntelX, an artificial intelligence-enabled in vitro diagnostic platform, to examine further improving outcomes for patients with chronic kidney disease (CKD) and its complications, in coordination with the Mount Sinai Health System. The goal of the first stage is to help improve guideline-based standard-of-care for optimal utilization of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software. hTTps://investors.renalytixai.com/news-releases/news-release-details/renalytixai-collaborate-astrazeneca Both of the above are just two aspects amongst many that are advanced, including a successful spinout of Verici with a retained shareholding, formation of Kantaro and many other advanced developments and partnerships, with Renalytix engaging with multiple healthcare institutions and national payors regarding additional partnership opportunities. Amongst the many developments, either of the above FDA approval or AstraZeneca collaboration could have a material and positive effect on the share price. With the AstraZeneca collaboration further demonstrating that Renalytix technology offering is an artificial intelligence-enabled in vitro diagnostic 'platform' capable of addressing other diseases, it will be interesting to see where else this powerful platform might be deployed. Renalytix Chief Executive Officer Mr. James McCullough, was previously CEO at Exosome Diagnostics, a cancer diagnostics firm that was acquired by Bio-Techne Corporation in 2018.
06/8/2020
08:01
74tom: The nice thing here is that a higher RENX share price is beneficial to Mount Sinai as it increases the value of their 15% stake. A larger portion of Kantaro may also reduce RENX's need for future equity funding, so there are a few reasons why this might happen. It's a fascinating & pretty unique situation that is unfolding.
21/7/2020
14:20
nimbo1: There will be plenty of pi's selling because it didn't double day one. They need to execute from an operational perspective - as and when they do share price will increase dramatically I would have thought. We are now tied to the nasdaq price and other than the insti's who purchased shares over there no other investors have heard of renx yet. Im sure when Stifel resume coverage and put out an investment note / renx release their first news on nasdaq you'll see interest pick up. also the share price has travelled quite a long way relatively quickly - you always get periods of distribution after such times...especially after raising money! The key thing is they have their money so the potential to be a great success is now in their hands : )
09/7/2020
11:38
74tom: Re. Distribution of shares in Verici, it seems logical to grant shares in the new entity on a 1-1 basis. The book value of Verici is $2m, so they’ve minimised the ex dividend in specie impact on the RENX share price (it’ll be about 2.7p), IMO better to do it this way than the way EKF split off RENX, which resulted in a 30% ex div in specie markdown. My opinion is that they’ll look to raise around £20m when they IPO, and the pre cash valuation will likely be similar to the RENX IPO (£45m). They simply wouldn’t bother with the spin off process to list for much less than this. However, even a much lower pre IPO valuation of £20-25m would still result in a very nice paper profit vs the current book valuation... So based on the above assumptions, I’m happy with the 1 year lock in - it’s worth it to be get in at the very bottom. What are your thoughts?
Renalytix Ai share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210308 09:12:05